A 67× gain in ELISA sensitivity is a result. What produced it is the experimental design, and that’s what this post examines.
Primer Length: A Non-Obvious Design Parameter
Four oligo-dT primer lengths were tested: 18, 22, 30, and 40 bases. Signal improved progressively from odT18 → odT22 → odT30. Then it dropped at odT40.
That’s not the result you’d predict by intuition. Short primers have weak initial association with their templates, which slows the reaction. Increasing length improves that association — up to a point. Beyond a certain length, the bulkier antibody-primer complex can begin to interfere with binding. The data puts the optimum at odT30, and that’s what both Exazym® reagent kits are built around.
Why this matters for your work: odT30 is a published optimum you can build on. If you’re developing a custom conjugate, you don’t need to characterize primer length from scratch. You have a tested starting point, with linearity confirmed at R² > 0.99.
The SARS-CoV-2 Benchmark: Reading the Experiment Carefully
The centerpiece of the paper is a direct comparison between a standard ELISA and a BOLD-amplified version of the same test. The experimental design is straightforward, and the details matter.
Both assays used:
- The same capture antibody (anti-SARS-CoV-2 spike mAb, clone DH6)
- The same detection antibody (clone AD10), labeled with odT30 in the amplified version and biotin in the standard
- The same starting sample concentration of spike protein, though as Figure 7 in the published paper shows, the BOLD-amplified version stayed quantifiable at far greater dilutions than the standard ELISA
- The same plate reader
The polymerase step and BrdU detection were added only to the amplified version. Everything else was matched.
Result: the BOLD-amplified assay detected spike protein at a lower limit of detection of 7.2 × 10⁻¹⁹ mol, compared with 4.8 × 10⁻¹⁷ mol for the standard ELISA, a 67-fold improvement. The deviation from linearity at the upper limit came from the luminometer’s detection range, not the assay itself.
This is a controlled, apples-to-apples comparison; the 67× reflects the amplification step alone.
Why this matters for your work: Most published sensitivity comparisons don’t control for everything. This one does, which makes 67× a clean number to cite.
What This Means for Your ELISA Sensitivity
The SARS-CoV-2 system is a benchmark. The method is biomarker-agnostic: it requires only that the detection antibody can carry an oligo-dT primer. The same published mechanism delivers ELISA sensitivity gains across IL-4 (50×), troponin I (180×), pTau181 (65×), and TNF-α (6×). The peer-reviewed paper is the root; those application notes are the branches.
Most researchers working with this method shouldn’t need to re-run optimization experiments. The Exazym® product line is built around that premise: each kit maps to a specific stage of the BOLD workflow.
- Antibody conjugation. If your detection antibody is already biotinylated, Exazym® StreptaClick® Primer binds directly to it. If you’re working with an unmodified antibody, the Exazym® ClickChem Conjugation Kit handles the chemistry. For IL-4, IL-6, and TNF-α, pre-conjugated Exazym® Antibody Pair Kits are available where conjugation is already complete.
- Signal amplification. The Exazym® Polymerase Reaction Kit initiates the reverse transcriptase reaction that builds the BOLD signal ladder.
- Signal detection. Detection kits are available in Biotin, HRP, APC, and PE formats, all on the Exazym® kits page.
The paper is open access.
Read the SLAS Technology paper →
Working on a specific low-abundance target? Reach out directly, and we can talk through whether BOLD is the right fit for your assay.
Contact the Exazym Support Team → · support@cavidi.se
We’ll be at ADLM 2026 in Anaheim, July 26–30, at Booth 3679. If you’re working on a low-abundance biomarker detection challenge and want to talk about what Exazym® can do in your context, come find us.